Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

849 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Extended interval dosing of natalizumab in multiple sclerosis.
Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, Pandey K, Donnelly S, Pawate S, Bomprezzi R, Smith D, Kolb C, Qureshi S, Okuda D, Kalina J, Rimler Z, Green R, Monson N, Hoyt T, Bradshaw M, Fallon J, Chamot E, Bucello M, Beh S, Cutter G, Major E, Herbert J, Frohman EM. Zhovtis Ryerson L, et al. Among authors: cutter g. J Neurol Neurosurg Psychiatry. 2016 Aug;87(8):885-9. doi: 10.1136/jnnp-2015-312940. Epub 2016 Feb 25. J Neurol Neurosurg Psychiatry. 2016. PMID: 26917698
Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF, Sandrock AW, Rudick RA, Simon JH, Simonian NA, Tsao EC, Whitaker JN; IMPACT Investigators. Cohen JA, et al. Among authors: cutter gr. Neurology. 2002 Sep 10;59(5):679-87. doi: 10.1212/wnl.59.5.679. Neurology. 2002. PMID: 12221157 Clinical Trial.
Eight-year follow-up study of brain atrophy in patients with MS.
Fisher E, Rudick RA, Simon JH, Cutter G, Baier M, Lee JC, Miller D, Weinstock-Guttman B, Mass MK, Dougherty DS, Simonian NA. Fisher E, et al. Among authors: cutter g. Neurology. 2002 Nov 12;59(9):1412-20. doi: 10.1212/01.wnl.0000036271.49066.06. Neurology. 2002. PMID: 12427893 Clinical Trial.
MRI as a marker for disease heterogeneity in multiple sclerosis.
Bielekova B, Kadom N, Fisher E, Jeffries N, Ohayon J, Richert N, Howard T, Bash CN, Frank JA, Stone L, Martin R, Cutter G, McFarland HF. Bielekova B, et al. Among authors: cutter g. Neurology. 2005 Oct 11;65(7):1071-6. doi: 10.1212/01.wnl.0000178984.30534.f9. Neurology. 2005. PMID: 16217061
849 results